- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears Image Processing Software with Emphasis on Nuclear Medicine Imaging Workflow
The InterView Fusion and InterView XP reportedly improve image quality for single-photon emission computed tomography (SPECT) and offer imaging tools specifically geared to common nuclear medicine studies ranging from bone imaging to cardiac assessment and lung imaging.
Specifically tailored to workflows for nuclear medicine and molecular imaging, the InterView™ Fusion (Mediso) and InterView XP (Mediso) multimodality (PET/SPECT/MRI/CT) image processing and reporting software have garnered 510(k) clearance from the Food and Drug Administration (FDA).
In addition to bolstering image quality for single-photon emission computed tomography (SPECT) with iterative reconstruction, the InterView software offers specialized tools for a variety of common nuclear medicine studies including cardiac, bone, thyroid, liver, and lung imaging, according to Mediso.
The company said the InterView software also features a variety of modules that facilitate automated lesion detection and segmentation as well as image denoising.
In addition to bolstering image quality for single-photon emission computed tomography (SPECT) with iterative reconstruction, the InterView software offers specialized tools for a variety of common nuclear medicine studies including bone imaging. (Images courtesy of Mediso.)
Mediso added that the vendor independent software can be utilized on stand-alone workstations or be incorporated seamlessly into physical or virtual servers of hospital information systems.
“The InterView software together with the AnyScan SPECT and SPECT/CT clinical systems provide a complete solution for all nuclear medicine routine and research application, and they demonstrate our continuous commitment to the molecular imaging market,” noted Istvan Bagamery, the founder and CEO of Mediso.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
